Arab Israeli Conflict
Middle East News
Hi Tech News
Mylan rejected Teva's $41 billion bid earlier this week.
Acquisition would create leading company with potential to transform global market for generics.
Teva sought stay of lower court ruling that favored developers of generic versions of its top selling multiple sclerosis drug.
In the early years of the state, Teva raised money on the newly established Tel Aviv Stock Exchange.
By GREER FAY CASHMAN
The Israeli pharmaceutical company is being sued in the US following an alleged price-fixing conspiracy worth "many billions of dollars."
By EYTAN HALON
The agency has said that the deals cost consumers billions annually in higher drug costs.
The successful Israeli-based generic medication manufacturer has been forced to downsize, but emphasized there will be no second round of restructuring or new site closures.
"The expected move-in date will be mid-2020," Teva SVP global human resources Mark Sabag told Globes.
By YVETTE J. DEANE
Only two weeks ago, Teva received approval for its newly-developed migraine drug known as Ajovy, raising hopes of improved financial fortunes.
The U.S. Food and Drug Administration approved a new migraine treatment Teva created, which has potentially 39 million Americans buyers.
The purchase initially sent share prices soaring by 12 percent.
By MAX SCHINDLER
The Education Ministry will cover the cost of tuition loans that will convert into grants after two years of teaching in the field.
By LIDAR GRAVÉ-LAZI
This comes as the company is laying off thousands of workers in an effort to balance its books
Please insert a valid email address